European countries should collaborate to reduce drug prices

INICIO/Informes | Posted 04/05/2015 post-comment0 Post your comment

According to a study published by the World Health Organization (WHO) on 26 March 2015 transparency and cooperation help to reduce high prices for new medicines.

Meds Cost Euros 2 V13L06

The report, entitled Access to new medicines in Europe: technical review of policy initiatives, opportunities for collaboration and research, finds that governments are finding it increasingly difficult to afford expensive new treatments for chronic conditions like cancer, type 2 diabetes and hepatitis C.

The study carried out by the WHO Regional Office for Europe shows that few of the 27 European countries studied have mechanisms in place to evaluate the cost-effectiveness of new drugs, a fact that is hampering value-assessment and decision-making processes.

Transparency is seriously lacking, according to the report; both the supply and prices of new medicines are often fixed in framework agreements between governments and pharmaceutical producers and the negotiation process is generally rather opaque. While countries like Germany and the UK have cost watchdogs that force companies to negotiate discount deals, the prices they pay often remain confidential. Countries need to strengthen cooperation and share their experiences if transparency is to be achieved and gaps in medicines pricing policies are to be filled.

The report therefore recommends that in the future:

  • Cooperation should be strengthened between governments, regulators and drug companies
  • Collaboration and transparency in policy-making should be increased
  • Particular focus should be given to chronic care, specialty medicines and rare diseases

The report also notes that while all countries across Europe are facing problems due to the high prices of new medicines, the challenge is even greater in low- and middle-income countries, where regulation mechanisms are less developed and health systems are weaker.

Related articles
WHO calls for better science-based regulations for biosimilars

WHO investigates use of a biological qualifier for biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: WHO

comment icon Comments (0)
Post your comment
Related content
PD biomarkers for biosimilar development and approval
Biomarker select V21K26
INICIO/Informes Posted 26/11/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010